Considering the lack of serum-based markers in the context of BTC, we evaluated circulating levels of CXCL1, CXCL10 and CXCL13 in a large cohort of BTC patients undergoing tumor resection between 2011 and 2017, with the aim to analyze their potential as diagnostic and prognostic markers in these patients. Here, CXCL10 is linked to neoplasm.